The coagulation system as a target for experimental therapy of human gliomas

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 3, 2003, Pages 399-404

  Loynes, James T ^a   Zacharski, L R ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

Blood coagulation; Glioma; Thrombosis; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; EPIGALLOCATECHIN; GREEN TEA EXTRACT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; MONOCLONAL ANTIBODY; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; PLACENTA PROTEIN 5; PLASMINOGEN ACTIVATOR INHIBITOR; RECOMBINANT HIRUDIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SERINE PROTEINASE INHIBITOR; SIMVASTATIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; XIMELAGATRAN; ZK 807843;

BLEEDING; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GLIOMA; HUMAN; META ANALYSIS; METASTASIS; REVIEW; THROMBOEMBOLISM; TUMOR GROWTH;

ANTICOAGULANTS; APROTININ; BLOOD COAGULATION; BRAIN NEOPLASMS; FACTOR XA; GLIOMA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; THROMBIN; THROMBOMODULIN; THROMBOPHILIA; THROMBOPLASTIN; URINARY PLASMINOGEN ACTIVATOR;

EID: 0038040747     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.3.399     Document Type: Review

References (55)

1. TROUSSEAU A: Phlegmasia alba dolens. In: Clinque Medicale de l'Hotel-Deiu de Paris (2nd Edn, Volume 3). JB Balliere, Paris (1865):654-712.
2. RATHER LJ: A Commentary on the Medical Writings of Rudolph Virchow. Norman Publishing, San Francisco (1990).
3. QUEVEDO JF, BUCKNER JC, SCHMIDT JL, DINAPOLI RP, O'FALLON JR: Thromboembolism in patients with high-grade glioma. Mayo Clin. Proc. (1994) 69(4):329-332.
4. DHAMI MS, BONA RD, CALOGERO JA, HELLMAN RM: Venous thromboembolism and high grade gliomas. Thromb. Haemost. (1993) 70(3):393-396.
5. MARRAS LC, GEERTS WH, PERRY JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer (2000) 89(3):640-646.
6. JOFFE SN: The prevention of postoperative deep vein thrombosis. S. Afr. Med. J. (1975) 49(5):153-156.
7. VALLADARES JB, HANKINSON J: Incidence of lower extremity deep vein thrombosis in neurosurgical patients. Neurosurgery (1980) 6(2):138-141.
8. CHAN AT, ATIEMO A, DIRAN LK et al.: Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J. Thromb. Thrombolysis (1999) 8(2):139-142.
9. LIU D, SHRIVER Z, QI Y, VENKATARAMAN G, SASISEKHARAN R: Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin. Thromb. Hemost. (2002) 28(1):67-78.
10. GUAN M, JIN J, SU B, LIU WW, LU Y: Tissue factor expression and angiogenesis in human glioma. Clin. Biochem. (2002) 35(4):321-325.
11. ORNSTEIN DL, MEEHAN KR, ZACHARSKI LR: The coagulation system as a target for the treatment of human gliomas. Semin. Thromb. Hemost. (2002) 28(1):19-28.
12. GUAN M, JIN J, SU B, LIU WW, LU Y: Tissue factor expression and angiogenesis in human glioma. Clin. Biochem. (2002) 35(4):321-325.
13. CONTRINI J, HAIR G, KRETZER DL, RICKLES FR: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat. Med. (1996) 2:209-215.
14. MUELLER BM, REISFELD RA, EDGINGTON TS, RUFF W: Expression of tissue factor by human melanoma cells promotes efficient hematogenous metastasis. Proc. Natl. Acad. Sci. USA (1992) 89:11832-11836.
15. NAKAGAWA K, ZHANG Y, TSUJI H et al.: The angiogenic effects of tissue factor on tumors and wounds. Semin. Thromb. Hemost. (1998) 24:207-210.
16. LAKKA SS, KONDURI SD, MOHANAM S, NICOLSON GL, RAO JS: In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. Clin. Exp. Metastasis (2000) 18(3):239-244.
17. KONDURI SD, RAO CN, CHANDRASEKAR N et al.: A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene (2001) 20(47):6938-6945.
18. RICKLES FR, SHOJI M, ABE K: The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int. J. Hematol. (2001) 73(2):145-150.
19. ABE K, SHOJI M, CHEN J et al.: Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl. Acad. Sci. USA (1999) 96(15):8663-8668.
20. SHOJI M, HANCOCK WW, ABE K et al.: Activation of coagulation and angiogenesis in cancer immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am. J. Pathol. (1998) 152(2):399-411.
21. OLLIVIER V, BENTOLILA S, CHABBAT J, HAKIM J, DE PROST D: Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated Factor VII. Blood (1998) 91(8):2698-2703.
22. PETERSEN LC, SPRECHER CA, FOSTER DC, BLUMBERG H, HAMAMOTO T, KISIEL W: Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry (1996) 35(1):266-272.
23. ORNSTEIN D, ZACHCHARSKI L: Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int. J. Hematol. (2001) 73:157-161.
24. OGIICHI T, HIRASHIMA Y, NAKAMURA S, ENDO S, KURIMOTO M, TAKAKU A: Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J. Neurooncol. (2000) 46(1):1-9.
25. YAMAHATA H, TAKESHIMA H, KURATSU J et al.: The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor. Int. J. Oncol. (2002) 20(5):921-928.
26. WANG H, UBL JJ, STRICKER R, REISER G: Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways. Am. J. Physiol. Cell Physiol. (2002) 283(5):C1351-C1364.
27. HIRANO H, LOPES MB, LAWS ER et al.: Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro-oncology (1999) 1(2):109-119.
28. RIEWALD M, KRAVCHENKO VV, PETROVAN RJ et al.: Gene induction by coagulation Factor Xa is mediated by activation of protease-activated receptor 1. Blood (2001) 97(10):3109-3116.
29. MARUNO M, YOSHIMINE T, ISAKA T et al.: Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. Cancer Lett. (1999) 146(2):169-172.
30. MOHANAM S, CHANDRASEKAR N, YANAMANDRA N et al.: Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene (2002) 21(51):7824-7830.
31. BHATTACHARYA A, LAKKA SS, MOHANAM S, BOYD D, RAO JS: Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin. Cancer Res. (2001) 7(2):267-276.
32. ZHANG X, FEI Z, BU X et al.: Expression and significance of urokinase type plasminogen activator gene in human brain gliomas. J. Surg. Oncol. (2000) 74(2):90-94.
33. THODIYIL P, KAKKAR AK: Can low-molecular-weight heparins improve outcome in patients with cancer? Cancer Treat. Rev. (2002) 28(3):151-155.
34. VON TEMPELHOFF GF, HARENBERG J, NIEMANN F, HOMMEL G, KIRKPATRICK CJ, HEILMANN L: Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int. J. Oncol. (2000) 16(4):815-824.
35. ZACHARSKI LR, LOYNES JT: The heparins and cancer. Curr. Opin. Pulm. Med. (2002) 8(5):379-382.
36. BROWN JR, KUTLER DJ: The effect of unfractionated versus low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Thromb. Haemost. (2001) 85(6):979-985.
37. ALBAN S, GASTPAR R: Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb. Haemost. (2001) 85(5):824-829.
38. MACDONALD RL, AMIDEI C, LIN G et al.: Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. Neurosurgery (1999) 45(2):245-251. Discussion 251-252.
39. SCHMIDT F, FAUL C, DICHGANS J, WELLER M: Low molecular weight heparin for deep vein thrombosis in glioma patients. J. Neurol. (2002) 249(10):1409-1412.
40. LENTSCHENER C, LI H, FRANCO D et al.: Intraoperatively-administered aprotinin and survival after elective liver resection for colorectal cancer metastasis. A preliminary study Fibrinolys. Proteolys. (1999) 13:39-45.
41. NAKADA M, YAMASHITA J, OKADA Y, SATO H: Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic rumors. J. Neuropathol. Exp. Neurol. (1999) 58(4):329-334.
42. PALMER JD, FRANCIS DA, ROATH OS, FRANCIS JL, IANNOTTI F: Hyperfibrinolysis during intracranial surgery: effect of high dose aprotinin. J. Neurol. Neurosurg. Psychiatry (1995) 58(1):104-106.
43. WONG WW, DIMITROULAKOS J, MINDEN MD, PENN LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia (2002) 16(4):508-519.
44. DENOYELLE C, VASSE M, KORNER M et al.: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (2001) 22(8):1139-1148.
45. ROSENSON RS, TANGNEY CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA (1998) 279(20):1643-1650.
46. SZCZEKLIK A, MUSIAL J, UNDAS A et al.: Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J. Am. Coll. Cardiol. (1999) 33(5):1286-1293.
47. SZCZEKLIK A, UNDAS A, MUSIAL J, GAJEWSKI P, SWADZBA J, JANKOWSKI M: Antithrombotic actions of statins. Med. Sci. Monit. (2001) 7(6):1381-1385.
48. DANGAS G, SMITH DA, UNGER AH et al.: Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb. Haemost. (2000) 83(5):688-692.
49. COLLI S, ELIGINI S, LALLI M et al.: Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arteriorscler. Thromb. Vasc. Biol. (1997) 17:265-272.
50. FERRO D, PARROTTO S, BASILI S et al.: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J. Am. Coll. Cardiol. (2000) 36:427-431.
51. FENTON JW II, SHEN GX, MINNEAR F et al.: Statins induce hypothrombotic states? Clin. Appl. Thromb. Hemost. (2000) 6:18-21.
52. PARRECCA E, DIFEBBO C, AMORE C et al.: Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients Thromb. Haemost. (2000) 84:789-793.
53. JONES KD, COULDWELL WT, HINTON DR et al.: Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem. Biophys. Res. Commun. (1994) 205(3):1681-1687.
54. MURAKAMI M, GOTO T, SAITO Y, GOTO S, KOCHI M, USHIO Y: The inhibitory effect of simvastatin on growth in malignant gliomas - with special reference to its local application with fibrin glue spray in vivo. Int. J. Oncol. (2001) 19(3):525-531.
55. YOKOYAMA S, HIRANO H, WAKIMURA N, SARIKER KP, DURATSU J: Inhibitory effect of epigallocatechin-gallate on brain tumor cell lines in vitro. Neuro-oncology (2001) 3(1):22-28.